一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

???????

???????
??????? ??? ???
?? ??:
191732-72-6
???:
???????
???(??):
???????
???:
Lenalidomide
???(??):
Revlimid;3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione;Lenalidomid;enaL;CC-5013;LenalidoMide (CC-5013);enalidomide;3-(7-amino-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione;3-(4-aMino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione
CBNumber:
CB3855432
???:
C13H13N3O3
??? ??:
259.26
MOL ??:
191732-72-6.mol
MSDS ??:
SDS

??????? ??

???
265-268 °C
?? ?
614.0±55.0 °C(Predicted)
??
1.460±0.06 g/cm3(Predicted)
?? ??
2-8°C
???
DMSO? ???(?? 30mg/ml)
?? ?? (pKa)
10.75±0.40(Predicted)
??? ??
??
??? ??
??? ??
??
???
???
??? ?? ?????? 1? ?? ??????. DMSO ??? -20°C?? ?? 3?? ?? ??? ? ????.
InChI
InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
InChIKey
GOTYRUGSSMKFNF-UHFFFAOYSA-N
SMILES
N1C(=O)CCC(N2CC3=C(C2=O)C=CC=C3N)C1=O
CAS ??????
191732-72-6(CAS DataBase Reference)
??
  • ?? ? ?? ??
  • ?? ? ???? ?? (GHS)
?? ???? ?? 20/21/22
????? 36/37
WGK ?? WGK 3
?? ?? IRRITANT
HS ?? 29339900
???? ??? 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects
Hazard Classifications Repr. 1B
STOT RE 2
?? ?? ??? 191732-72-6(Hazardous Substances Data)
????(GHS): Health Hazard (GHS08)
?? ?: Warning
??·?? ??:
?? ??·?? ?? ?? ?? ?? ?? ? ?? ?? P- ??
H373 ??? ?? ?? ???? ??(??, ??? ?? ??? ?? ??? ??)? ??? ??? ? ?? ?? ???? ?? - ?? ?? ?? 2 ?? P260, P314, P501
??????:
P202 ?? ?? ?? ??? ?? ???? ??? ???? ???.
P260 ??·?·??·???·??·...·????? ???? ???.
P280 ????/???/???/?????? ?????.
P308+P313 ?? ?? ??? ???? ???? ??· ??? ????.
P405 ???? ?????.
P501 ...? ??? / ??? ?? ???.

??????? C??? ??, ??, ??

??

Lenalidomide is a kind of antitumor drugs that developed by American biological pharmaceutical companies. Its chemical structure is similar with thalidomide. It differing in the presence of an amino moiety in the 4-position and removal of one of the carbonyls of the phthaloyl ring. This derivative evolved from a structural-based effort to eliminate the adverse effects (somnolence, neuropathy, and teratogenicity) of thalidomide while maintaining or enhancing the appealing attributes. It has many functions such as anti-tumor, immune regulation and anti-angiogenesis. It can inhibit the secretion of inflammatory cytokines, and increase the secretion of peripheral blood mononuclear anti-inflammatory cytokines. Vitro tests show that lenalidomide can inhibit the hyperplasia of some cell lines such as namalwa cell. It can inhibit the growth of patients’ multiple myeloma cells and MM1S cell. In addition, lenalidomide also can inhibit the expression of oxidase-2 (COX-2), but it has no effect on COX-1. Two multicenter randomized double-blind placebo-controlled clinical studies evaluate the safety and curative effect of lenalidomide that is used for multiple myeloma. The primary efficacy end point of the studies is time to progression (TTP). The interim analysis shows that TTP of the combination group is significantly superior to dexamethasone group. Recent clinical research results show that lenalidomide not only has curative effect on treating MDS and MM, but also on treating myeloma, leukemia, metastatic renal cell carcinoma, solid tumor, idiopathic generalized amyloidosis and systemic bone marrow fibrosis disease with marrow unripe.

??? ??

Yellow Solid

??

In December 2005, the US Food and Drug Administration (FDA) approved lenalidomide to be used in the treatment of myelodysplastic syndrome (MDS).
In March 2006, the FDA approved lenalidomide that was produced by American Celgene Biological Pharmaceutical Companies to be used in the treatment of multiple myeloma (MM).
On September 23, 2011, the European Medicines Agency (EMA) released information that they have confirmed that the benefits of lenalidomide(trade name: Revlimid) to be used in the treatment of patients group that was approved outweighed the risks. Meanwhile they warned the doctor the risk of the drug to cause new cancer cases. Lenalidomide has been used with dexamethasone to treat adult patients with multiple myeloma that has received at least one treatment. Three new studies show that the incidence of new cancer will be increased in the patients with newly diagnosed multiple myeloma treated by lenalidomide and other combined treatment increased incidence of cancer.

??

Lenalidomide (Revlimid, CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM.

??

Lenalidomide is a thalidomide analog known to have immunomodulatory properties. Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis. This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells. It is used in the therapy of multiple myeloma.

??

ChEBI: Lenalidomide is a dicarboximide that consists of 1-oxoisoindoline bearing an amino substituent at position 4 and a 2,6-dioxopiperidin-3-yl group at position 2. Inhibits the secretion of TNF-alpha. It has a role as an angiogenesis inhibitor, an antineoplastic agent and an immunomodulator. It is a member of isoindoles, a dicarboximide, a member of piperidones and an aromatic amine.

benefits

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions.

??????? ?? ?? ? ???

???

?? ??


??????? ?? ??

???( 764)?? ??
??? ?? ??? ?? ?? ? ??
Chongqing jooe co., ltd
+86-15223382610
info@jooe.com China 15971 58
AFINE CHEMICALS LIMITED
+86-571-85134551 +86-18958018566
info@afinechem.com China 15079 58
Hefei TianRui Pharmaceutical Chemical Co., Ltd.
+86-0551-68665055 +86-+86-18616906106
sales@trywchem.com China 187 58
SHANDONG BOYUAN PHARMACEUTICAL CO., LTD.
+86-531-88625728 +86-15806417970
sales@boyuanpharm.com China 181 58
Taizhou Creating Bio-pharm co., ltd.
0576-88827176; +8613586099526
post@creatingbiopharm.com China 224 58
Guangzhou Tosun Pharmaceutical Ltd
+86-020-61855200-902 +86-18124244216
info@upharm.cn China 897 58
Improve Medical Technology(Nanxiong) Co.,Ltd
+86-13711621707
Jimin211@foxmail.com China 21 58
Shaanxi Dideu Medichem Co. Ltd
+86-17392712779
1097@dideu.com China 3992 58
Hebei Yanxi Chemical Co., Ltd.
+86-17531190177
faithe@yan-xi.com China 5853 58
Henan Bao Enluo International TradeCo.,LTD
+86-17331933971
deasea125996@gmail.com China 2472 58

??????? ?? ??:

Copyright 2019 ? ChemicalBook. All rights reserved
类乌齐县| 进贤县| 平湖市| 襄垣县| 镇江市| 鹤壁市| 绵竹市| 偃师市| 襄城县| 龙岩市| 满城县| 克拉玛依市| 额敏县| 文安县| 四川省| 化德县| 宜章县| 溆浦县| 盈江县| 翁源县| 蕉岭县| 新闻| 嘉定区| 鸡东县| 四子王旗| 兴宁市| 明光市| 漳平市| 恭城| 大埔区| 连州市| 应城市| 大荔县| 拉萨市| 克拉玛依市| 柏乡县| 洮南市| 长武县| 淮北市| 广灵县| 台江县|